In a narrow vote, Food and Drug Administration advisers recommended Tuesday that the agency approve the country's first RSV vaccine for older people, a shot from Pfizer for people ages 60 and up. Those who voted "no" based on the vaccine's safety profile largely worried about its potential association with Guillain-Barré syndrome, or GBS, a rare neurological disorder that damages nerve cells and causes muscle weakness or paralysis. Bavarian Nordic expects to have late-stage trial data for its RSV vaccine, which targets the same demographic, by the middle of the year